Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Sexually Transmitted Diseases
|
July 26, 2005
Costs and effects of chlamydial screening: dynamic versus static modeling
Robert Welte, Maarten Postma, Reiner Leidl, et al.
Expert Opinion on Pharmacotherapy
|
October 22, 2002
Cost-effectiveness of widespread screening for Chlamydia trachomatis
Maarten J Postma, Robert Welte, Servaas A Morré
Pharmacoeconomics
|
August 27, 2004
A decision chart for assessing and improving the transferability of economic evaluation results between countries
Robert Welte, Talitha Feenstra, Hans Jager, et al.
Pharmacoeconomics - Open
|
June 24, 2022
Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis
Zeki Kocaata, Thomas Wilke, Franz Fischer, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen
|
April 5, 2024
Health-related quality of life (HRQoL) in German early benefit assessment: The importance of disease-specific instruments
Lisa Kramer, Malte Moos, Bastian Thaa, et al.
Sexually Transmitted Diseases
|
April 8, 2006
Prediction of costs, effectiveness, and disease control of a population-based program using home sampling for diagnosis of urogenital Chlamydia trachomatis Infections
Berit Andersen, Jens Gundgaard, Mirjam Kretzschmar, et al.
Tobacco Control
|
November 30, 2006
Mortality, morbidity and costs attributable to smoking in Germany: update and a 10-year comparison
Simone Neubauer, Robert Welte, Alexandra Beiche, et al.
Pharmacoeconomics
|
September 13, 2005
The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine
Robert Welte, Caroline L Trotter, W John Edmunds, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
April 13, 2011
Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany
Sarah Dewilde, Bernd Brüggenjürgen, Christoph Nienaber, et al.
International Journal of Public Health
|
August 5, 2016
Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review
Oliver Damm, Julian Witte, Stefanie Wetzka, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Sexually Transmitted Diseases
|
July 26, 2005
Costs and effects of chlamydial screening: dynamic versus static modeling
Robert Welte, Maarten Postma, Reiner Leidl, et al.
Expert Opinion on Pharmacotherapy
|
October 22, 2002
Cost-effectiveness of widespread screening for Chlamydia trachomatis
Maarten J Postma, Robert Welte, Servaas A Morré
Pharmacoeconomics
|
August 27, 2004
A decision chart for assessing and improving the transferability of economic evaluation results between countries
Robert Welte, Talitha Feenstra, Hans Jager, et al.
Pharmacoeconomics - Open
|
June 24, 2022
Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis
Zeki Kocaata, Thomas Wilke, Franz Fischer, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen
|
April 5, 2024
Health-related quality of life (HRQoL) in German early benefit assessment: The importance of disease-specific instruments
Lisa Kramer, Malte Moos, Bastian Thaa, et al.
Sexually Transmitted Diseases
|
April 8, 2006
Prediction of costs, effectiveness, and disease control of a population-based program using home sampling for diagnosis of urogenital Chlamydia trachomatis Infections
Berit Andersen, Jens Gundgaard, Mirjam Kretzschmar, et al.
Tobacco Control
|
November 30, 2006
Mortality, morbidity and costs attributable to smoking in Germany: update and a 10-year comparison
Simone Neubauer, Robert Welte, Alexandra Beiche, et al.
Pharmacoeconomics
|
September 13, 2005
The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine
Robert Welte, Caroline L Trotter, W John Edmunds, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
April 13, 2011
Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany
Sarah Dewilde, Bernd Brüggenjürgen, Christoph Nienaber, et al.
International Journal of Public Health
|
August 5, 2016
Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review
Oliver Damm, Julian Witte, Stefanie Wetzka, et al.
Page
of 2